354 related articles for article (PubMed ID: 25785551)
1. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
2. Total cost comparison in relapsed/refractory multiple myeloma.
Durie B; Binder G; Pashos C; Khan Z; Hussein M; Borrello I
J Med Econ; 2013; 16(5):614-22. PubMed ID: 23281721
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Chen CC; Parikh K; Abouzaid S; Purnomo L; McGuiness CB; Hussein M; Wade RL
J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
[TBL] [Abstract][Full Text] [Related]
5. Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective.
Matsela LM; Cleary S; Wilkinson T
Cost Eff Resour Alloc; 2022 Dec; 20(1):69. PubMed ID: 36510230
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
8. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Teitelbaum A; Ba-Mancini A; Huang H; Henk HJ
Oncologist; 2013; 18(1):37-45. PubMed ID: 23299776
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
Hari P; Ung B; Abouzaid S; Agarwal A; Parikh K
Future Oncol; 2019 Dec; 15(35):4045-4056. PubMed ID: 31625415
[No Abstract] [Full Text] [Related]
10. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
Leukemia; 2018 Mar; 32(3):712-718. PubMed ID: 28848227
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
[TBL] [Abstract][Full Text] [Related]
12. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
13. A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
Hollmann S; Moldaver D; Goyert N; Grima D; Maiese EM
J Manag Care Spec Pharm; 2019 Apr; 25(4):449-459. PubMed ID: 30917078
[TBL] [Abstract][Full Text] [Related]
14. [Retrospective Analysis of Bortezomib or Lenalidomide for Very Elderly Patients with Newly Diagnosed Multiple Myeloma].
Okayama Y; Takakuwa T; Otomaru I; Horiuchi M; Miura A; Araki T; Fujitani Y; Yamamura R
Gan To Kagaku Ryoho; 2021 Jun; 48(6):815-819. PubMed ID: 34139730
[TBL] [Abstract][Full Text] [Related]
15. Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Gooding S; Lau IJ; Sheikh M; Roberts P; Wong J; Dickens E; Bullement A; Elvidge J; Lee D; Ramasamy K
PLoS One; 2015; 10(9):e0136207. PubMed ID: 26367874
[TBL] [Abstract][Full Text] [Related]
16. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
Hagiwara M; Panjabi S; Sharma A; Delea TE
J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
[No Abstract] [Full Text] [Related]
18. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
